Juhun Lee1, Jong Mi Kim1, Yoon Hee Lee1, Gun Oh Chong1, Dae Gy Hong2. 1. Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. 2. Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea dghong@knu.ac.kr.
Abstract
BACKGROUND/AIM: There have not been enough recent studies investigating the incidence or efficacy of dose reduction in adjuvant chemotherapy for epithelial ovarian cancer. This study examined whether patients who needed dose reduction showed poorer survival outcomes. PATIENTS AND METHODS: From 2011 to 2021, 102 patients were included in the study. Patients who underwent neoadjuvant chemotherapy and those with early-stage disease were excluded. Patients were divided into two groups: those who had a ≥60% dose reduction during the whole period of first-line adjuvant chemotherapy, and those with dose reductions <60%. Of the 102 patients, 38 (37.3%) underwent dose reduction ≥60%. RESULTS: PFS was significantly longer in the group whose dose reductions were ≥60%, whereas OS was not significant. CONCLUSION: A dose reduction of ≥60%, determined by patients' medical conditions, during first-line of adjuvant chemotherapy does not negatively influence survival outcomes, such as OS and PFS, in advanced epithelial ovarian cancer.
BACKGROUND/AIM: There have not been enough recent studies investigating the incidence or efficacy of dose reduction in adjuvant chemotherapy for epithelial ovarian cancer. This study examined whether patients who needed dose reduction showed poorer survival outcomes. PATIENTS AND METHODS: From 2011 to 2021, 102 patients were included in the study. Patients who underwent neoadjuvant chemotherapy and those with early-stage disease were excluded. Patients were divided into two groups: those who had a ≥60% dose reduction during the whole period of first-line adjuvant chemotherapy, and those with dose reductions <60%. Of the 102 patients, 38 (37.3%) underwent dose reduction ≥60%. RESULTS: PFS was significantly longer in the group whose dose reductions were ≥60%, whereas OS was not significant. CONCLUSION: A dose reduction of ≥60%, determined by patients' medical conditions, during first-line of adjuvant chemotherapy does not negatively influence survival outcomes, such as OS and PFS, in advanced epithelial ovarian cancer.
Authors: Alexander B Olawaiye; James J Java; Thomas C Krivak; Michael Friedlander; David G Mutch; Gretchen Glaser; Melissa Geller; David M O'Malley; Robert M Wenham; Roger B Lee; Diane C Bodurka; Thomas J Herzog; Michael A Bookman Journal: Gynecol Oncol Date: 2018-08-19 Impact factor: 5.482
Authors: T Sivakumaran; L Mileshkin; P Grant; L Na; A DeFazio; M Friedlander; A Obermair; P M Webb; G Au-Yeung Journal: Gynecol Oncol Date: 2020-05-04 Impact factor: 5.482
Authors: Janelle M Fauci; Jenny M Whitworth; Kellie E Schneider; Akila Subramaniam; Bin Zhang; Peter J Frederick; Larry C Kilgore; J Michael Straughn Journal: Gynecol Oncol Date: 2011-06-11 Impact factor: 5.482
Authors: Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Lisa Barroilhet; Kian Behbakht; Andrew Berchuck; Lee-May Chen; Mihaela Cristea; Maria DeRosa; Eric L Eisenhauer; David M Gershenson; Heidi J Gray; Rachel Grisham; Ardeshir Hakam; Angela Jain; Amer Karam; Gottfried E Konecny; Charles A Leath; Joyce Liu; Haider Mahdi; Lainie Martin; Daniela Matei; Michael McHale; Karen McLean; David S Miller; David M O'Malley; Sanja Percac-Lima; Elena Ratner; Steven W Remmenga; Roberto Vargas; Theresa L Werner; Emese Zsiros; Jennifer L Burns; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2021-02-02 Impact factor: 11.908